We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

MAST GROUP

Mast Group is an independent manufacturer and supplier of diagnostic products for clinical, industrial and veterinary... read more Featured Products: More products

Download Mobile App





Mast Group Introduces New MAST CARBA PAcE for Rapid Carbapenemase Detection

By LabMedica International staff writers
Posted on 21 Nov 2019
Mast Group Ltd. More...
(Liverpool, UK) was amongst the 4,500 exhibitors from 70 countries that presented their products and services at the MEDICA 2019 Trade Fair held in Düsseldorf, Germany from 18-21st November. MEDICA is the world's largest medical trade fair for medical technology, electromedical equipment, laboratory equipment, diagnostics and pharmaceuticals. MEDICA provides the medical device industry with a central market for innovative products and systems that result in an important contribution to the efficiency and quality of patient care. The combination of product shows with international congresses, forums, as well as expert workshops, and the exchange of professional views make MEDICA a meeting point for international professionals from various fields in the medical sector.

Mast is a manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing. The company manufactures microbiology and molecular biology products, as well as other infectious disease and autoimmune diagnostics, using a variety of technologies. At the 2019 edition of MEDICA, Mast introduced the new MAST CARBA PAcE for rapid carbapenemase detection in Pseudomonas spp., Acinetobacter spp. and Enterobacterales.

The company’s MAST ASSURE and CRYOBANK range also featured on the booth this year alongside its extensive range of MASTDISCS for antimicrobial susceptibility and resistance marker testing. MAST ASSURE’s extensive range contains both polyvalent and monovalent diagnostic antisera for the identification of Salmonella spp according to the expression of somatic antigens. Bacterial serotype can be determined by both slide agglutination and test tube agglutination methods.

The company’s MASTDISCS AST is available as an extensive range of antibiotic susceptibility test discs. Mast also offers an extensive range of MASTDISCS Combi antibiotic resistance detection sets for identification and differentiation of enzyme types using a combination disc technology, incorporating specific inhibitors to accurately detect extended spectrum ß-lactamase (ESßL), AmpC cephalosporinase, Metallo ß-lactamase (MBL) including VIM, IMP and NDM Klebsiella pneumoniae carbapenemase (KPC) and OXA-48 like carbapenemases.

Related Links:
Mast Group Ltd.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automated Clinical Chemistry Analyzer
Envoy 500+
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.